Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $18.11
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $18.11
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $18.11, but opened at $18.71. Zentalis Pharmaceuticals shares last traded at $18.71, with a volume of 1 shares.
Zentalis製藥公司(納斯達克代碼:ZNTL-GET Rating)的股價週四盤前大幅上漲。該股此前收於18.11美元,開盤報18.71美元。Zentalis PharmPharmticals的股票最新報18.71美元,成交量為1股。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
A number of research firms have recently commented on ZNTL. SVB Leerink lowered their target price on Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating for the company in a research report on Thursday, November 10th. Wedbush dropped their price objective on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating for the company in a research note on Monday, November 14th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a research report on Monday, November 14th. Oppenheimer dropped their price target on Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, November 10th. Finally, Morgan Stanley reduced their price objective on Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday, November 11th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $46.56.
一些研究公司最近對ZNTL發表了評論。SVB Leerink在11月10日(週四)的一份研究報告中將Zentalis PharmPharmticals的目標價從42.00美元下調至27.00美元,併為該公司設定了“跑贏大盤”的評級。11月14日,週一,韋德布什在一份研究報告中將Zentalis製藥公司的股票目標價從51.00美元下調至32.00美元,併為該公司設定了“跑贏大盤”的評級。在11月14日星期一的一份研究報告中,富國銀行將Zentalis製藥公司的股票目標價從52.00美元下調至46.00美元。奧本海默在11月10日星期四的一份研究報告中將Zentalis PharmPharmticals的目標價從80.00美元下調至50.00美元,併為該公司設定了“跑贏大盤”的評級。最後,摩根士丹利在11月11日(星期五)的一份研究報告中將Zentalis PharmPharmticals的目標價從60.00美元下調至55.00美元,並對該股設定了“增持”評級。根據MarketBeat的數據,9位研究分析師對該股的評級為買入,該公司的平均評級為“買入”,平均目標價為46.56美元。
Zentalis Pharmaceuticals Stock Performance
Zentaris製藥類股表現
The stock has a fifty day moving average of $21.14 and a 200-day moving average of $24.48. The company has a market cap of $1.15 billion, a PE ratio of -4.27 and a beta of 1.80.
該股的50日移動均線為21.14美元,200日移動均線為24.48美元。該公司市值11.5億美元,市盈率為-4.27,貝塔係數為1.80。
Insider Activity
內幕活動
Institutional Inflows and Outflows
機構資金流入和流出
Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Zentalis Pharmaceuticals by 284.2% in the 1st quarter. JPMorgan Chase & Co. now owns 105,579 shares of the company's stock worth $4,871,000 after buying an additional 78,102 shares during the period. US Bancorp DE grew its holdings in Zentalis Pharmaceuticals by 378.9% during the 1st quarter. US Bancorp DE now owns 1,451 shares of the company's stock worth $67,000 after acquiring an additional 1,148 shares in the last quarter. MetLife Investment Management LLC increased its position in Zentalis Pharmaceuticals by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 19,665 shares of the company's stock valued at $907,000 after purchasing an additional 7,139 shares during the period. Rhumbline Advisers raised its holdings in shares of Zentalis Pharmaceuticals by 7.0% in the 1st quarter. Rhumbline Advisers now owns 37,923 shares of the company's stock valued at $1,750,000 after purchasing an additional 2,475 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 79.2% in the 1st quarter. Integral Health Asset Management LLC now owns 215,000 shares of the company's stock worth $9,920,000 after purchasing an additional 95,000 shares during the period.
幾家對衝基金和其他機構投資者最近買賣了該公司的股票。摩根大通在第一季度增持了Zentalis PharmPharmticals的股票,增幅為284.2%。摩根大通在此期間又購買了78,102股,目前持有105,579股該公司股票,價值4,871,000美元。美國Bancorp DE在第一季度增持了378.9%的Zentalis製藥公司的股份。US Bancorp DE現在擁有1451股該公司股票,價值6.7萬美元,此前在上個季度又購買了1148股。大都會人壽投資管理公司在第一季度將其在Zentalis製藥公司的頭寸增加了57.0%。大都會人壽投資管理公司目前持有該公司19,665股股票,價值907,000美元,在此期間又購買了7,139股。Rhumbline Advisers在第一季度將其在Zentalis PharmPharmticals的股票持有量增加了7.0%。Rhumbline Advisers現在擁有37,923股該公司股票,價值1,750,000美元,上個季度又購買了2,475股。最後,Integral Health Asset Management LLC在第一季度將其在Zentalis PharmPharmticals的股票頭寸提高了79.2%。Integral Health Asset Management LLC現在擁有21.5萬股該公司的股票,價值992萬美元,在此期間又購買了9.5萬股。
About Zentalis Pharmaceuticals
關於Zentaris製藥公司
(Get Rating)
(獲取評級)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis製藥公司是一家臨牀階段的生物製藥公司,專注於發現和開發用於治療各種癌症的小分子療法。它的主要候選產品包括WEE1的抑制劑ZN-c3,這是一種蛋白質酪氨酸激酶,正處於治療晚期實體腫瘤的第二階段臨牀試驗;作為單一療法治療晚期實體腫瘤的第1/2階段臨牀試驗,以及正在進行的與鉑耐藥卵巢癌患者的聯合化療的1b階段臨牀試驗;以及腫瘤不可知的、可預測的生物標記物的第二階段單一治療試驗。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 免費獲取StockNews.com關於Zentalis製藥的研究報告(ZNTL)
- MarketBeat:回顧一週12/26-12/30
- 科技狗:是時候咬一口這些股票了
- 這筆收購會讓微軟成為熊市買入者嗎?
- 金塔拉治療公司是一顆隱藏的寶石嗎?
- 你應該熱身到Generac股票過冬嗎?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zentaris製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zentalis製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。